JP2019530751A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530751A5 JP2019530751A5 JP2019540310A JP2019540310A JP2019530751A5 JP 2019530751 A5 JP2019530751 A5 JP 2019530751A5 JP 2019540310 A JP2019540310 A JP 2019540310A JP 2019540310 A JP2019540310 A JP 2019540310A JP 2019530751 A5 JP2019530751 A5 JP 2019530751A5
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- pharmaceutical composition
- item
- cannabinoid
- trace
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930003827 cannabinoid Natural products 0.000 claims description 66
- 239000003557 cannabinoid Substances 0.000 claims description 66
- 239000004480 active ingredient Substances 0.000 claims description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 35
- 150000003505 terpenes Chemical class 0.000 claims description 30
- 235000007586 terpenes Nutrition 0.000 claims description 30
- 229940065144 cannabinoids Drugs 0.000 claims description 18
- 244000025254 Cannabis sativa Species 0.000 claims description 12
- 235000008697 Cannabis sativa Nutrition 0.000 claims description 12
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 10
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims description 10
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims description 6
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims description 5
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 claims description 5
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 claims description 5
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 claims description 5
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 claims description 5
- 235000001510 limonene Nutrition 0.000 claims description 5
- 229940087305 limonene Drugs 0.000 claims description 5
- 229930007744 linalool Natural products 0.000 claims description 5
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 claims description 5
- FQTLCLSUCSAZDY-UHFFFAOYSA-N (+) E(S) nerolidol Natural products CC(C)=CCCC(C)=CCCC(C)(O)C=C FQTLCLSUCSAZDY-UHFFFAOYSA-N 0.000 claims description 4
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 claims description 4
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 claims description 4
- FQTLCLSUCSAZDY-ATGUSINASA-N Nerolidol Chemical compound CC(C)=CCC\C(C)=C\CC[C@](C)(O)C=C FQTLCLSUCSAZDY-ATGUSINASA-N 0.000 claims description 4
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 4
- 229950011318 cannabidiol Drugs 0.000 claims description 4
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims description 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- WASNIKZYIWZQIP-AWEZNQCLSA-N nerolidol Natural products CC(=CCCC(=CCC[C@@H](O)C=C)C)C WASNIKZYIWZQIP-AWEZNQCLSA-N 0.000 claims description 4
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- -1 pinene Chemical compound 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000006199 nebulizer Substances 0.000 claims description 2
- 230000006576 neuronal survival Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000006200 vaporizer Substances 0.000 claims description 2
- 229960003453 cannabinol Drugs 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- 235000005273 Canna coccinea Nutrition 0.000 claims 1
- 240000008555 Canna flaccida Species 0.000 claims 1
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims 1
- 241001471082 Colocasia bobone disease-associated cytorhabdovirus Species 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 claims 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023017412A JP2023058599A (ja) | 2016-10-11 | 2023-02-08 | 神経変性疾患を処置するためのカンナビノイド含有複合混合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662406764P | 2016-10-11 | 2016-10-11 | |
| US62/406,764 | 2016-10-11 | ||
| PCT/US2017/055989 WO2018071452A1 (en) | 2016-10-11 | 2017-10-10 | Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017412A Division JP2023058599A (ja) | 2016-10-11 | 2023-02-08 | 神経変性疾患を処置するためのカンナビノイド含有複合混合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530751A JP2019530751A (ja) | 2019-10-24 |
| JP2019530751A5 true JP2019530751A5 (https=) | 2020-11-19 |
| JP7225103B2 JP7225103B2 (ja) | 2023-02-20 |
Family
ID=60382587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540310A Active JP7225103B2 (ja) | 2016-10-11 | 2017-10-10 | 神経変性疾患を処置するためのカンナビノイド含有複合混合物 |
| JP2023017412A Pending JP2023058599A (ja) | 2016-10-11 | 2023-02-08 | 神経変性疾患を処置するためのカンナビノイド含有複合混合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017412A Pending JP2023058599A (ja) | 2016-10-11 | 2023-02-08 | 神経変性疾患を処置するためのカンナビノイド含有複合混合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10653640B2 (https=) |
| EP (1) | EP3525823B1 (https=) |
| JP (2) | JP7225103B2 (https=) |
| CN (2) | CN109963595B (https=) |
| AU (3) | AU2017344040A1 (https=) |
| CA (1) | CA3039413A1 (https=) |
| IL (1) | IL265902B2 (https=) |
| WO (1) | WO2018071452A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| WO2018205022A1 (en) | 2017-05-08 | 2018-11-15 | Inmed Pharmaceuticals Inc. | Ocular drug delivery formulation |
| JP2020520966A (ja) | 2017-05-22 | 2020-07-16 | ジービーエス グローバル バイオファーマ，インコーポレイテッド | Ｔｒｐｖ１を標的にするミルセン及びカンナビノイド含有組成物 |
| CA3089994A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
| JP2021524465A (ja) | 2018-05-22 | 2021-09-13 | ジービーエス グローバル バイオファーマ，インコーポレイテッド | Ｔｒｐｖ１モジュレーションに使用するためのカンナビノイド及び／又はテルペン |
| WO2020077153A1 (en) | 2018-10-10 | 2020-04-16 | Canopy Holdings, LLC | Synthesis of cannabigerol |
| AU2019413789B2 (en) * | 2018-12-29 | 2025-05-29 | Buzzelet Development And Technologies Ltd. | Isolated or synthetic cannabinoid compositions with selected terpene blend and methods of use thereof |
| KR20220080045A (ko) * | 2019-04-24 | 2022-06-14 | 인메드 파마슈티컬스 인코포레이티드 | 신경보호를 위한 칸나비노이드의 사용을 위한 조성물 및 방법 |
| CA3144983A1 (en) * | 2019-06-28 | 2020-12-30 | Gbs Global Biopharma, Inc. | Treatment of pain using allosteric modulator of trpv1 |
| US12576093B2 (en) | 2019-07-17 | 2026-03-17 | Mannkind Corporation | Pharmaceutical composition for subcutaneous administration |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| AU2020358869A1 (en) | 2019-10-03 | 2022-04-14 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| CN113694049B (zh) * | 2020-05-21 | 2022-11-22 | 汉义生物科技（北京）有限公司 | 大麻素类化合物及其在治疗帕金森症中的应用 |
| US20220047525A1 (en) * | 2020-08-17 | 2022-02-17 | Pike Therapeutics, Inc. | Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids |
| US20220110910A1 (en) * | 2020-08-18 | 2022-04-14 | Gbs Global Biopharma, Inc. | Cannabinoid-containing complex mixtures for the treatment of cytokine release syndrome while preserving key anti-viral immune reactions |
| PL4124336T3 (pl) | 2021-07-30 | 2024-02-26 | Cannamedical Pharma Gmbh | Plaster przezśluzówkowy obejmujący kannabinoid i/lub opioid |
| CN113368086B (zh) * | 2021-08-11 | 2021-12-03 | 龙麻(上海)医药研发有限责任公司 | 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用 |
| EP4408404A4 (en) * | 2021-09-28 | 2025-10-29 | Gbs Global Biopharma Inc | Formulations containing cannabinoids for Parkinsonian movement disorders |
| WO2024148117A2 (en) * | 2023-01-04 | 2024-07-11 | Florascience Inc. | Methods of treating neurodegenerative diseases or conditions |
| WO2024160792A1 (en) | 2023-01-30 | 2024-08-08 | Cannamedical Pharma Gmbh | Improved transmucosal patch comprising a cannabinoid and/or an opioid |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58500845A (ja) | 1981-06-04 | 1983-05-26 | デラウェア・ケミカルス・コーポレーション | ポンプ |
| US4778810A (en) | 1987-01-08 | 1988-10-18 | Nastech Pharmaceutical Co., Inc. | Nasal delivery of caffeine |
| US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
| EA003328B1 (ru) | 1998-04-08 | 2003-04-24 | Эли Лилли Энд Компани | Легочная и назальная доставка ралоксифена |
| US6403126B1 (en) | 1999-05-26 | 2002-06-11 | Websar Innovations Inc. | Cannabinoid extraction method |
| DE10051427C1 (de) | 2000-10-17 | 2002-06-13 | Adam Mueller | Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte |
| CA2533400C (en) * | 2001-02-14 | 2017-01-03 | Gw Pharma Limited | Cannabinoids pharmaceutical formulations |
| GB2391865B (en) * | 2002-08-14 | 2005-06-01 | Gw Pharma Ltd | Improvements in the extraction of pharmaceutically active components from plant materials |
| EP1587482A4 (en) | 2003-01-31 | 2010-08-25 | Technion Res & Dev Foundation | INFLAMMATORY COMPOSITIONS AND ITS USES |
| GB2434312B (en) * | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| GB2448535A (en) * | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
| US20110257256A1 (en) * | 2008-07-31 | 2011-10-20 | Bionoria Research Gmbh | Cannabinoids for use in treating or preventing cognitive impairment and dementia |
| US8277781B2 (en) | 2009-03-13 | 2012-10-02 | Luitpold Pharmaceuticals, Inc. | Device for intranasal administration |
| CA2760460C (en) | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
| US9066910B2 (en) | 2010-04-15 | 2015-06-30 | Steven Rosenblatt | Methods and compositions of cannabis extracts |
| GB2491118B (en) * | 2011-05-20 | 2015-12-30 | Otsuka Pharma Co Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| GB201111261D0 (en) | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| WO2014145490A2 (en) * | 2013-03-15 | 2014-09-18 | Biotech Institute, Llc | Breeding, production, processing and use of specialty cannabis |
| CN105228602A (zh) | 2013-05-24 | 2016-01-06 | 雀巢产品技术援助有限公司 | 使用薄荷醇、芳樟醇和/或冰素治疗或预防神经变性障碍 |
| US9763991B2 (en) * | 2013-06-13 | 2017-09-19 | Cannabis Science International Holding B.V. | Composition for the treatment of neurobehavioral disorders |
| US20150057342A1 (en) | 2013-08-21 | 2015-02-26 | Cannabics Pharmaceuticals Inc | Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof |
| EP4151234A1 (en) | 2014-05-29 | 2023-03-22 | Fresh Cut Development, LLC | Stable cannabinoid formulations |
| GB2527590A (en) | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| WO2016133824A1 (en) | 2015-02-16 | 2016-08-25 | Axim Biotechnologies, Inc. | Cosmetic and topical compositions comprising cannabigerol |
| AU2016225026A1 (en) * | 2015-02-27 | 2017-09-07 | Canopy Growth Corporation | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| WO2017193072A1 (en) * | 2016-05-06 | 2017-11-09 | Harvest Direct Enterprises Llc | The manufacturing methods, compositions, and medical applications of orally administered cannabis pharmaceuticals |
-
2017
- 2017-10-10 CN CN201780071100.5A patent/CN109963595B/zh active Active
- 2017-10-10 CN CN202310039015.8A patent/CN115887440A/zh active Pending
- 2017-10-10 CA CA3039413A patent/CA3039413A1/en active Pending
- 2017-10-10 AU AU2017344040A patent/AU2017344040A1/en not_active Abandoned
- 2017-10-10 US US15/729,565 patent/US10653640B2/en active Active
- 2017-10-10 WO PCT/US2017/055989 patent/WO2018071452A1/en not_active Ceased
- 2017-10-10 JP JP2019540310A patent/JP7225103B2/ja active Active
- 2017-10-10 IL IL265902A patent/IL265902B2/en unknown
- 2017-10-10 EP EP17800639.1A patent/EP3525823B1/en active Active
-
2020
- 2020-04-09 US US16/844,713 patent/US11980592B2/en active Active
-
2023
- 2023-02-08 JP JP2023017412A patent/JP2023058599A/ja active Pending
- 2023-08-30 AU AU2023222872A patent/AU2023222872A1/en not_active Abandoned
-
2024
- 2024-05-13 US US18/663,034 patent/US20250108016A1/en active Pending
-
2025
- 2025-08-11 AU AU2025213702A patent/AU2025213702A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530751A5 (https=) | ||
| EP3538122B1 (en) | Cannabinoid formulations and method of making the same | |
| Grotenhermen et al. | The therapeutic potential of cannabis and cannabinoids | |
| Szaflarski et al. | Cannabis, cannabidiol, and epilepsy—from receptors to clinical response | |
| EP3160451B1 (en) | Buccal and sublingual cannabinoid formulations and method of making the same | |
| WO2009043395A3 (en) | Pharmaceutical composition | |
| IL275704B2 (en) | Oral pharmaceutical formulation comprising cannabinoids and poloxamer | |
| CN109952098A (zh) | 大麻素的自乳化组合物 | |
| JP2014519525A5 (https=) | ||
| CA3038541A1 (en) | An oral composition of extracted cannabinoids and methods of use thereof | |
| CN109789124A (zh) | 大麻属组合物 | |
| KR20210071939A (ko) | 통증을 치료하기 위한 조성물 및 방법 | |
| JP2019523283A (ja) | 大麻組成物 | |
| CA3079537A1 (en) | Tetrahydrocannabinol modulators | |
| AU2018100928A4 (en) | Composition and method for opioid sparing | |
| AU2021215262A1 (en) | Composition and method for treating chronic pain | |
| Niu et al. | The effects of hispidulin on bupivacaine-induced neurotoxicity: role of AMPK signaling pathway | |
| US20230087359A1 (en) | Cannabinoid compositions and methods of use thereof | |
| US20210137877A1 (en) | Products and methods for using cannabidiol in combination with melatonin to induce sleep | |
| US20180193304A1 (en) | Phytoterpenoid facilitation of therapeutic onset and efficacy of sublingual cannabinoid administration | |
| GB2597170A (en) | Diluents for compositions of cannabinoids and uses thereof | |
| US10736869B2 (en) | Compositions and methods related to cannabinoids, terpenoids and essential oils | |
| US20040248970A1 (en) | CBD-delta8-THC composition | |
| da Rocha Lapa et al. | Vasorelaxant and hypotensive effects of the extract and the isolated flavonoid rutin obtained from Polygala paniculata L. | |
| JP2024516682A (ja) | 鼻腔用睡眠製剤 |